• About Us
• Caris Target Now^™ Molecular Profiling
• Carisome^™ Microvesicle Technology
• Careers
• Contact Us

Caris Life Sciences^™

Caris Life Sciences^™ was founded because of an idea — that better diagnostics can improve patients' lives and ultimately improve healthcare for everyone. This drives everything we do, from diagnosing thousands of patients each day, to creating innovative tools to improve diagnosis and treatment of many complex diseases.

Our efforts are focused on providing innovative services supporting diagnosis, prognosis and theranosis:

Caris Target Now^™ combines comprehensive molecular pathology and tumour profiling with evidence-based clinical literature to provide information needed to personalise therapy for patients with cancer. Currently available.

Carisome^™ Microvesicle Technology is a versatile, proprietary blood-based technology that is being studied for potential utility as an aid in the diagnosis of common cancers such as colon, breast, lung and prostate cancer, as well as other complex diseases. Currently under development.

Through these services, Caris arms doctors with information necessary for three key stages of medical care — diagnosis, prognosis and theranosis.

Caris Europe are currently seeking sales professionals in the UK, Switzerland, Germany, Italy, BeNeLux and the Nordics. Please follow the links to our careers page for more information.

Caris Life Sciences’ global operations are located in Basel, Switzerland. For more information, visit www.CarisLifeSciences.eu. Caris is a privately held leader in biosciences, headquartered in Irving, Texas, U.S.A. Additional U.S. operations are located in Phoenix, Arizona.